175 related articles for article (PubMed ID: 36225746)
21. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
22. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis.
Signorelli J; Lei M; Lam J; Jalbut M; Amrein PC; Fathi AT; Hobbs G; Hock H; McAfee SL; Letourneau AR; Narayan R; Brunner A
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e883-e889. PubMed ID: 32917574
[TBL] [Abstract][Full Text] [Related]
23. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.
Guinan K; Mathurin K; Au Y; Schuh AC; Bui CN; Chai X; Lachaine J
Curr Oncol; 2022 Oct; 29(10):7524-7536. PubMed ID: 36290869
[TBL] [Abstract][Full Text] [Related]
25. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
26. Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy.
Mishra P; Agrawal N; Bhurani D; Agarwal NB
Indian J Hematol Blood Transfus; 2020 Jan; 36(1):64-70. PubMed ID: 32174692
[TBL] [Abstract][Full Text] [Related]
27. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
Garciaz S; Hospital MA; Alary AS; Saillard C; Hicheri Y; Mohty B; Rey J; D'Incan E; Charbonnier A; Villetard F; Maisano V; Lombardi L; Ittel A; Mozziconacci MJ; Gelsi-Boyer V; Vey N
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454930
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
[TBL] [Abstract][Full Text] [Related]
30. Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia.
Fujino K; Ureshino H; Yoshida T; Ichinohe T
Cureus; 2023 May; 15(5):e39481. PubMed ID: 37362503
[TBL] [Abstract][Full Text] [Related]
31. Panobinostat sensitizes AraC-resistant AML cells to the combination of azacitidine and venetoclax.
Zhao J; Wu S; Wang D; Edwards H; Thibodeau J; Kim S; Stemmer P; Wang G; Jin J; Savasan S; Taub JW; Ge Y
Biochem Pharmacol; 2024 Feb; ():116065. PubMed ID: 38373594
[TBL] [Abstract][Full Text] [Related]
32. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Matthews AH; Perl AE; Luger SM; Loren AW; Gill SI; Porter DL; Babushok DV; Maillard IP; Carroll MP; Frey NV; Hexner EO; Martin ME; McCurdy SR; Stadtmauer EA; Paralkar VR; Bruno XJ; Hwang WT; Margolis D; Pratz KW
Blood Adv; 2022 Jul; 6(13):3997-4005. PubMed ID: 35507945
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax Plus Azacitidine as a Bridge Treatment to Allogeneic Stem Cell Transplantation in Unfit Patients with Acute Myeloid Leukemia.
Chen TT; Lin CC; Lo WJ; Hsieh CY; Lein MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539418
[TBL] [Abstract][Full Text] [Related]
34. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis.
Oh SM; Byun JM; Chang E; Kang CK; Shin DY; Koh Y; Hong J; Kim TS; Choe PG; Park WB; Kim NJ; Yoon SS; Kim I; Oh MD
Sci Rep; 2021 Nov; 11(1):22160. PubMed ID: 34773060
[TBL] [Abstract][Full Text] [Related]
35. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
[TBL] [Abstract][Full Text] [Related]
36. Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
Arora S; Zainaldin C; Bathini S; Gupta U; Worth S; Bachiashvili K; Bhatia R; Godby K; Jamy O; Rangaraju S; Diamond B; Oliver JD; Salzman D; Di Stasi A; Vachhani P
Leuk Res; 2022 Jun; 117():106844. PubMed ID: 35487134
[TBL] [Abstract][Full Text] [Related]
37. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
Stevens BM; Jones CL; Pollyea DA; Culp-Hill R; D'Alessandro A; Winters A; Krug A; Abbott D; Goosman M; Pei S; Ye H; Gillen AE; Becker MW; Savona MR; Smith C; Jordan CT
Nat Cancer; 2020 Dec; 1(12):1176-1187. PubMed ID: 33884374
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Tey A; Shaw B; Cardamone L; Shepherd S; Paul E; Rogers B; Shortt J
Eur J Haematol; 2021 Aug; 107(2):181-189. PubMed ID: 33829584
[TBL] [Abstract][Full Text] [Related]
39. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
Cojocari D; Smith BN; Purkal JJ; Arrate MP; Huska JD; Xiao Y; Gorska A; Hogdal LJ; Ramsey HE; Boghaert ER; Phillips DC; Savona MR
Haematologica; 2022 Apr; 107(4):825-835. PubMed ID: 33853293
[TBL] [Abstract][Full Text] [Related]
40. Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
Michallet M; Sobh M; Morisset S; Deloire A; Raffoux E; de Botton S; Caillot D; Chantepie S; Girault S; Berthon C; Bertoli S; Lepretre S; Leguay T; Castaigne S; Marolleau JP; Pautas C; Malfuson JV; Veyn N; Braun T; Gastaud L; Suarez F; Schmidt A; Gressin R; Bonmati C; Celli-Lebras K; El-Hamri M; Ribaud P; Dombret H; Thomas X; Bergeron A
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):311-318. PubMed ID: 34895843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
